论文部分内容阅读
为研究丙型肝炎病毒基因型与其对α-干扰素(INF-α)疗效的关系,作者等对70例经临床、生化及组织学证实的非甲非乙型肝炎病人应用α-干扰素治疗。病人和方法70例中13例每天应用INF-α200万U,20例每天400万U,37例每天600万U,每周3次,疗程共16周。治疗前用多聚酶链反应(PCR)检测血清的HCV RNA,三套引物(A_1、A_2,B_1、B_2和C_1、C_2)和探针(A、B、C)分别来自5’端非编码区HC-J1,NS3区的HCV-J,以及NS5区的HCV-K2,并且各自用于扩增221-bp的序列、458-bp序列以及231-bp序列,或者用于与之杂交,即5’-NC-PCR、NS3-PCR和
In order to study the relationship between hepatitis C virus genotypes and the efficacy of IFN-α, 70 patients with non-A, non-B hepatitis confirmed clinically, biochemically and histologically were treated with interferon-α . Patients and Methods Seventy of the 70 patients underwent INF-a 2 million U daily, 20 daily 4 million U, and 37 daily 6 million U three times weekly for a total of 16 weeks. Serum HCV RNA was detected by polymerase chain reaction (PCR) before treatment, and three sets of primers (A_1, A_2, B_1, B_2 and C_1, C_2) and probes (A, B and C) -J1, HCV-J in the NS3 region, and HCV-K2 in the NS5 region, and each used to amplify a 221-bp sequence, a 458-bp sequence and a 231-bp sequence or to hybridize with it, -NC-PCR, NS3-PCR and